Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-3067 · 1 trial · 1 indication
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration and is used as a measure of lung function. Mixed-effect model with repeated measures (MMRM) was used for the analyses.
| Arm | Type | Description |
|---|---|---|
| ABBV-3067 50 mg + Placebo for ABBV-2222 | EXPERIMENTAL | Participants received ABBV-3067 50 mg tablet orally once daily (QD) plus placebo matching ABBV-2222 capsule, orally QD for 28 days. |
| ABBV-3067 150 mg + Placebo for ABBV-2222 | EXPERIMENTAL | Participants received ABBV-3067 150 mg tablet orally QD plus placebo matching ABBV-2222 capsule, orally QD for 28 days. |
| ABBV-3067 150 mg + ABBV-2222 10 mg | EXPERIMENTAL | Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 10 mg capsule orally QD for 28 days. |
| ABBV-3067 150 mg + ABBV-2222 30 mg | EXPERIMENTAL | Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 30 mg capsule orally QD for 28 days. |
| ABBV-3067 150 mg + ABBV-2222 100 mg | EXPERIMENTAL | Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 100 mg capsule orally QD for 28 days. |
| ABBV-3067 150 mg + ABBV-2222 200 mg | EXPERIMENTAL | Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 200 mg capsule, orally QD for 28 days. |
| ABBV-3067 150 mg + ABBV-2222 300 mg | EXPERIMENTAL | Participants received ABBV-3067 150 mg tablet orally QD plus ABBV-2222 300 mg capsule, orally QD for 28 days. |
| Placebo for ABBV-3067 + Placebo for ABBV-2222 | PLACEBO_COMPARATOR | Participants received placebo matching ABBV-3067 tablet orally QD plus placebo matching ABBV-2222 capsule, orally QD for 28 days. |
| Name | Type | Description |
|---|---|---|
| ABBV-3067 | DRUG | Tablet taken orally. |
| Placebo ABBV-3067 | DRUG | Tablet taken orally. |
| ABBV-2222 | DRUG | Capsule taken orally. |
| Placebo ABBV-2222 | DRUG | Capsule taken orally. |
Inclusion Criteria: * Confirmed clinical diagnosis of Cystic Fibrosis (CF) who are homozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation * Stable pulmonary status * Lung function \>= 40 and \<= 90% of predicted normal for age, gender and height at Screening Exclusion Cr...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
ABBV-3067 is an investigational small molecule being developed for the treatment of cystic fibrosis. It is a Phase 2 drug candidate that has been studied in a completed clinical trial involving 78 participants. The drug is intended for use in adults aged 18 years and older with cystic fibrosis.
ABBV-3067 is being developed by AbbVie Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol ABBV. The company has conducted a Phase 2 clinical trial of the drug for cystic fibrosis, which has been completed.
ABBV-3067 is in Phase 2 clinical development. It has completed a Phase 2 study, meaning it is still investigational and has not been approved by regulatory authorities. The drug is being studied for the treatment of cystic fibrosis in adult patients.
ABBV-3067 has been studied in one clinical trial, identified as NCT03969888. This was a Phase 2, randomized, double-blind, placebo-controlled study of ABBV-3067 alone and in combination with ABBV-2222 for cystic fibrosis. The trial enrolled 78 participants and has been completed.
No, ABBV-3067 is not the same as ABBV-2222. They are separate investigational drugs developed by AbbVie. In the clinical trial NCT03969888, ABBV-3067 was studied both alone and in combination with ABBV-2222 to evaluate their effects in patients with cystic fibrosis.